Gabapentin Tablet, Film Coated
Product Images NDC 70518-4532

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 70518-4532). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mm2 (Gabapentin 600mg 70518 4532 01)

Gabapentin 600 mg film-coated tablet packaging label showing quantity of 1 tablet. Label includes NDC 70518-4532-01, repackaged by RemedyRepack Inc., Indiana, PA. Storage instructions and dosage guidance to see insert are also visible.*

FDA Label Image

Remedy_label (Remedy Label)

Gabapentin 600 mg oral tablets, film-coated, packaged in a box containing 100 tablets. The label shows the product name, strength, quantity per box, and indicates it is repackaged by RemedyRepack Inc., Indiana, PA. Additional storage instructions and lot information are also visible.*

FDA Label Image

Equation (Equation)

An equation showing the formula for calculating creatinine clearance (CLCr) as a function of age, weight, and serum creatinine, with an adjustment factor for female patients. This text is typically found in drug prescribing information or pharmacokinetic sections.*

FDA Label Image

Fig-1 (Fig 1)

A line graph depicting mean pain scores over an 8-week period comparing placebo and Gabapentin 3600 mg/day. The x-axis represents weeks with a 4-week dose titration period followed by a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10. Gabapentin shows a decreasing pain score trend compared to placebo.*

FDA Label Image

Fig-2 (Fig 2)

A line graph showing mean pain score over a 7-week period for patients treated with placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day. The graph includes a 3-week dose titration period and a 4-week fixed dose period, with pain scores decreasing more for gabapentin groups compared to placebo.*

FDA Label Image

Fig-3 (Fig 3)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies.' It displays data for two studies comparing placebo (PBO) with different dosages of Gabapentin (GBP) measured in milligrams. Study 1 shows 12% responders for placebo and 29% for GBP 3600 mg. Study 2 shows 14% responders for placebo, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Statistical significance is indicated with p-values below 0.01 and 0.001.*

FDA Label Image

Fig-4 (Fig 4)

A scatter plot chart showing the difference percentage against daily dose in mg for Gabapentin. Data points for three studies labeled as study a, study b, and study c are depicted using different square symbols, illustrating differences across doses of 600 mg, 900 mg, 1200 mg, and 1800 mg.*

FDA Label Image

Structure (Structure)

Chemical structure of gabapentin, showing a cyclohexane ring with an amino group and an acetic acid side chain attached to the same carbon.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.